Anna V. Galkin

Anna V. Galkin

Auto-generated profile, based on publicly available information

Anna V. Galkin

Axelia Oncology, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2024 in Urology Herald
Verified
Journal Article
Open access
PDF file
NGN. G. Galkina
N. G. Galkina
AGA. V. Galkin
A. V. Galkin
Introduction. Numerous studies have suggested that lower urinary tract infections may be involved in the development of overactive bladder (OAB) in patients who are resistant to standard treatment. In these cases, treatment targeting all stages of disease progression could be beneficial.Objective. To evaluate the efficacy of Vesusten® in management of OAB in women with chronic recurrent cystitis.Materials & methods. The study involved 40 patients diagnosed with OAB and chronic recurrent cystitis. All patients received Vesusten® as therapy for OAB. They received 5 mg of the medication intramuscularly three times per week for a total of 10 doses. The study included three stages: a screening period lasting up to 14 days; the stage for assessing the effectiveness of therapy (42 days from the start of therapy, including the therapy period + further follow-up after the end of therapy); follow-up period — 180 days + 14 days from completion of treatment.Results. It was revealed Vesusten® clinical effectiveness on the severity of OAB symptoms and the quality of life of patients. hree weeks after the end of treatment, there was a statistically significant decrease in the severity of OAB symptoms on the Patient Perception Index of Urgency and Symptoms (PPIUS) (2.2 ± 1.0 vs 0.95 ± 1.0 points) and TUFS (28.4 ± 11.6 vs 5. 1 ± 6.4 points), a decrease in the number of urinations during the day (11.5 ± 2.2 vs 8.8 ± 2.7 episodes) and at night (3.5 ± 1.8 vs 1.4 ± 1.5 episodes) time (p < 0.001). The nighttime urination frequency decreased by more than 2.5 times, while the proportion of patients who did not wake up at night for urination increased from 10 % to 35%. Evaluation of the Overactive Bladder Questionnaire (OAB-Q) after the completion of treatment compared with the initial data showed a statistically significant improvement in quality of life related to the severity of OAB symptoms (24.8 ± 7.5 vs 15.7 + 6.4 points; p < 0.001), and with general health status (74.0 ± 31.7 vs 57.6 ± 22.1 points; p = 0.0087). The average duration of the relapse-free period, including the course of Vesusten® treatment and the follow-up period, significantly increased to 42.90 ± 9.64 weeks in comparison with the duration of the relapse-free period before patients’ inclusion in the study — 17.96 ± 7.75 weeks (p < 0.001). During the clinical study, eight women experienced exacerbations of chronic cystitis (20%).Conclusion. Study results suggest that the drug Vesusten® may be an effective treatment for OAB in combination with chronic recurrent cystitis. Based on our findings, we believe that Vesusten® can be considered as a potential treatment option for patients with chronic cystitis.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
AGAnna V. Galkin
Anna V. Galkin
FMFrancesca Mercuri
Francesca Mercuri
NWNicholas West
Nicholas West
PZPing Zhang
Ping Zhang
WZWeiguang Zeng
Weiguang Zeng
PKPhil Kearney
Phil Kearney
Background: Treatment approaches that engage both the innate and adaptive immune response have the potential to transform anti-cancer therapy, especially in settings of checkpoint inhibitor insensitivity or acquired resistance. Toll-like receptors (TLRs) are a class of targets that mediate the initial cellular response to external pathogens or endogenous alarmins, activating downstream pro-inflammatory cascades and leading to the activation and recruitment of key innate subsets. TLR2 is a cell surface receptor, expressed predominantly on macrophages, dendritic cells (DC), neutrophils and subsets of NK and T cells. TLR2 signaling plays important role in NK and T cell cytolytic cell functions, as well as DC and macrophage activation. AXA-042 is a novel synthetic TLR2/6 agonist designed for systemic delivery to re-engage the innate immune response to help overcome tumour immune escape. Methods: In vitro potency and selectivity of AXA-042 was assessed across a panel of human and mouse HEK-blue TLR reporter assays. AXA-042 activity was profiled relative to other TLR agonists in human PBMC cytokine release assays. AXA-042 in vivo efficacy was evaluated in the EMT6 and CT26 syngeneic tumour models. The Nanostring nCounter™ Mouse PanCancer Immune Profiling Panel was used to identify AXA-042 tumour-localized and peripheral response signatures. Results: AXA-042 demonstrated potent and selective activity in murine and human TLR2/6 reporter assays and a differential PBMC cytokine release profile relative to other TLR agonists in vitro. Systemic delivery (QW, IV or IP) of AXA-042 significantly inhibited EMT6 and CT26 tumour growth, which was accompanied by an increase in circulating plasma levels of IL6, IL12 and CXCL10. Combination with anti-PD-1 Ab further potentiated anti-tumour response, resulting in approximately 30-40% tumour regressions. AXA-042 anti-tumour effects were accompanied by increased activation of the tumour-infiltrating myeloid cells, including DCs and macrophages, and a reduction in the M2 TAM subset. Nanostring analysis confirmed TLR and IFNγ pathway engagement and revealed an induction of gene signatures associated with macrophage, DC and NK functions. Longitudinal studies to characterize whole blood biomarkers associated with response are currently in progress. Conclusion: AXA-042 was well tolerated in vivo and demonstrated innate response engagement and anti-tumour efficacy as monotherapy and in combination with anti-PD-1 immunotherapy. AXA-042 has completed GLP toxicology studies and initiation of Phase 1/1b trial is planned for early 2022. Citation Format: Anna V. Galkin, Francesca Mercuri, Nicholas West, Ping Zhang, Weiguang Zeng, Grant McLachlan, Michael Bettess, Ian Holmes, David Jackson, Chris Smith, Christophe Demaison, Tobias Bald, Phil Kearney. AXA-042 - a novel systemic TLR2/6 agonist for anti-tumor therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3502.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
BEBedrich Eckhardt
Bedrich Eckhardt
KMKellie Mouchemore
Kellie Mouchemore
YLYang Liao
Yang Liao
WSWei Shi
Wei Shi
FMFrancesca Mercuri
Francesca Mercuri
AGAnna Galkin
Anna Galkin
Background Treatment approaches that engage both the innate and adaptive immune response have the potential to transform anti-cancer therapy, especially in settings of checkpoint inhibitor insensitivity. Toll-like receptors (TLRs) mediate the initial cellular response to external pathogens or endogenous alarmins, activating downstream pro-inflammatory cascades associated with innate cell activation and recruitment. AXA-042 is a novel synthetic TLR2/6 agonist designed for systemic delivery to re-engage the innate immune response to help overcome tumor immune escape. Once-a-week treatment with AXA-042 led to 87% growth inhibition of syngeneic EMT6 tumors. Single cell sequencing analysis was completed to characterize the immediate impact of systemic TLR2/6 activation on the tumor microenvironment. Methods Female Balb/c mice bearing orthotopic EMT6.5 mammary tumors received a single intravenous treatment of saline or AXA-042 (10 μg/mouse). Equal numbers of viable cells were recovered by flow cytometry from collagenase-digested tumors (n=3/group) 24 hours after treatment and pooled prior to loading onto a Chromium Single Cell Chip. 10x Genomics single-cell transcriptome libraries were prepared from each sample and sequenced with Illumina NextSeq 550 sequencing platform. Cell type annotation based on the ImmGen database was determined using the SingleR package. Differential gene expression analyses were completed to identify AXA-042 responsive gene signatures in cell subsets that included at least 10 cells. The identified genes were required to be expressed in at least 3 cells. Results AXA-042 treatment decreased the total number of tumor-associated macrophages, monocytes, fibroblasts, endothelial, epithelial and stromal cells within 24 hours of treatment. A parallel increase in neutrophils, B cells, NKT and activated CD4 and CD8 T cells was observed. Re-clustering of myeloid populations revealed AXA-042-induced shifts in the macrophage, monocyte and neutrophil clusters. Differential expression analysis within the TLR2 positive myeloid cells demonstrated AXA-042-mediated engagement of pathways associated with antigen processing and presentation, Fc receptor signaling and immune hypersensitivity in monocytes; granulocyte chemotaxis, lipid metabolism and iron sequestration in neutrophils; and cellular response to bacterial lipopeptide, stress response to metal ions and arginine metabolism in macrophages Conclusions Systemic AXA-042 treatment led to a reorganization of the tumor microenvironment within 24 hours of treatment. AXA-042 altered the myeloid cell subset profiles, promoted the influx of activated T cells and reduced tumor cell viability. AXA-042 has completed GLP toxicology studies and is currently undergoing evaluation in a Phase 1 clinical trial (ACTRN12622000993796) in advanced solid tumors. Trial Registration ACTRN12622000993796 Ethics Approval The study was approved by the Austin Health Animal Ethics Committee, approval number 05640.

25 September 2025 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
NGN.G. Galkina
N.G. Galkina
RPRussia Penza
Russia Penza
AGA.V. Galkin
A.V. Galkin
ORO.A. Rodina
O.A. Rodina
RPRussia Regional Bureau Of Forensic Medical Examination; Penza
Russia Regional Bureau Of Forensic Medical Examination; Penza
Introduction. The search for pathogenetic mechanisms of recurrence of urinary tract infection (UTI) is an important link in choosing a treatment method. Knowledge of the histopathological changes in the bladder wall will help to develop an evidence-based treatment. Materials and methods. We enrolled 58 female patients with recurrent uncomplicated bacterial UTI. All of patients underwent video cystoscopy with a biopsy of the bladder wall using the "cold-cup" forceps method. Spearman correlation analysis was performed to assess the strength of association (correlation) between clinical data, the severity of changes on histological examination and the total score of the Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF Scale). Differences at p < 0.05 were considered statistically significant. Results. To standardize the results, a scoring scale was developed and used in this study to describe histopathological changes of urinary bladder biopsy specimens. Urothelial status, percent of mucosa denuded of urothelium, severity of chronic inflammation and of lamina propria sclerosis were studied. Hystopathological analysis confirmed the presence of chronic inflammation in all 58 patients (100%), accompanied by sclerosis in 70% of cases and violation of the integrity of the urothelium in 91% of cases. Conclusion. Our data indicate that chronic recurrent bacterial infections of the urinary tract are associated with a violation of the integrity of the transitional cell epithelium of the bladder wall. Insufficiency of urothelial function can be caused by UTI, and conversely, deficiency of the urothelium of the bladder wall can be a risk factor for chronic UTI.

1 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
SZSamantha Zaharevitz
Samantha Zaharevitz
RSRichard Salamone
Richard Salamone
CJCarie Jackson
Carie Jackson
KGKerri Grove
Kerri Grove
SBSergio Briones
Sergio Briones
DKDeborah A Knee
Deborah A Knee
Background: Ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) is expressed in gastrointestinal malignancies and catalyzes the hydrolysis of adenosine triphosphate (ATP), creating an immunosuppressive microenvironment by reducing the cytotoxic antitumor immune response, enhancing the proliferation and polarization of immunosuppressive cells, and increasing neovascularization. Blocking the hydrolase activity of ENTPD2 increases extracellular ATP and triggers a sustained proinflammatory response in the tumor microenvironment. In this report, we describe the development and characterization of a first-in-class monoclonal anti-ENTPD2 antibody, KAZ954, and surrogate anti-mouse ENTPD2 (mENTPD2) antibody, capable of potently inhibiting the ATP hydrolase activity of ENTPD2 and inducing antibody-dependent cellular cytotoxicity (ADCC). Methods: The ability of KAZ954 to inhibit ENTPD2-induced conversion of ATP to adenosine diphosphate (ADP) was evaluated. In vitro, NIH/3T3 cells engineered to express human or cyno-ENTPD2 and RKO cancer cell lines with endogenous ENTPD2 expression were used. In vivo, 4T1 syngeneic cell lines expressing mENTPD2 were generated, which have a luciferase molecule attached to the plasma membrane to measure extracellular ATP. The shift in ATP:ADP ratio was verified by matrix-assisted laser desorption/ionization imaging analysis. To assess the ADCC-inducing ability of KAZ954, a lactate dehydrogenase release assay was run using peripheral blood mononuclear cell (PBMCs) and RKO as effector and target cells, respectively. Two different ENTPD2-engineered syngeneic tumor models were used to study pharmacodynamics and the potential for single agent, and combinatorial, efficacy. Endpoint measurements included flow cytometry of tumor and blood and serum cytokine analysis. RASLseq was used to further identify RNA changes in mouse syngeneic tumor models treated with anti-mENTPD2. Results: KAZ954 potently inhibited the hydrolysis of ATP to ADP in NIH/3T3 cells, expressing exogenous human or cyno ENTPD2, and in RKO cell lines. KAZ954 IgG was able to bind ENTPD2 on RKO cell lines and Fcγ receptors on PBMCs, inducing RKO cell lysis and LDH release by ADCC. However, the KAZ954 F(ab’)2 fragment, although able to bind ENTPD2, was unable to induce RKO cell lysis due to its inability to bind to Fcγ receptors. Preclinical syngeneic tumor models treated with a surrogate mENTPD2 antibody demonstrated that the blockade of ENTPD2 hydrolase activity results in a delay in tumor growth which is further augmented in combination with immune checkpoint inhibitors or further blockade of the adenosine pathway. Evaluation of the in vivo responses to KAZ954 treatment revealed an increase in ATP:ADP ratio; an increase in intra-tumoral monocytes, NK cells, peripheral CD8+ T cells, macrophages, and CD11b+ dendritic cells, and a gene signature consistent with immune activation in the tumor. Conclusion:  KAZ954 binds to and inhibits the hydrolase activity of ENTPD2, leading to an increased intratumoral ATP:ADP ratio and a systemic inflammatory response. Citation Format: Samantha Zaharevitz, Richard Salamone, Carie Jackson, Kerri Grove, Sergio Briones, David Kim, Jian Shi, Kenneth Ng, Marina Harris, Chris Lee, Eric Peters, Anna Galkin, Lisa Guerrettaz, Deborah A Knee. Determining the mechanism of action of the anti-ENTPD2 antibody, KAZ954 [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr PR015.

8 June 2025 in Urology Herald
Verified
Journal Article
Open access
PDF file
NGN. G. Galkina
N. G. Galkina
AGA. V. Galkin
A. V. Galkin
ETE. V. Tokareva
E. V. Tokareva
Introduction. Chronic uncomplicated recurrent cystitis denotes the presence of frequent disease exacerbations in the absence of complicating factors. The identification of inflammatory process markers within the bladder wall is of paramount importance, as these markers enable the detection of inflammation in cases of normal urine test results and facilitate the prediction of recurrence risk and the severity of cystitis progression.Objective. To investigate the cytokine profile in blood and urine samples of female patients diagnosed with chronic recurrent cystitis.Materials & methods. The prospective study enrolled 33 female participants with a confirmed diagnosis of chronic (recurrent) uncomplicated cystitis. At the time of blood and urine sample collection, all study participants presented with recurrent chronic pelvic pain and/or pressure, bladder discomfort, and lower urinary tract symptoms. All patients in the study group underwent cystoscopy within bladder wall biopsy. The control group comprised 27 healthy women of reproductive age. The investigation involved the analysis of calprotectin, interleukin-6 (IL-6), tumour necrosis factor, and vascular endothelial growth factor (VEGF) levels in urine and blood samples from both study groups.Results. Statistically significant differences were identified in the levels of blood calprotectin, vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and urine calprotectin. The concentrations of these cytokines were elevated in the study group compared to the control group. Notably, while Student’s t-test for blood calprotectin approached the significance threshold (p ≈ 0.05), urine calprotectin demonstrated robust diagnostic significance (p = 0.0000). Elevated urinary VEGF levels were observed in the study group patients, suggesting an association with bladder wall hypoxia and inflammation. A direct moderate-strength correlation was established between chronic recurrent cystitis and both urinary calprotectin (R = 0.649, p = 0.0000) and leukocyturia (R = 0.519, p = 0.0000). Pathomorphological examination of the bladder wall in all study group patients revealed an inflammatory process, with 63.6% of cases exhibiting squamous cell metaplasia of the urothelium in the Lieto triangle. The potential key role of increased S100A8/ S100A9 expression on the bladder squamous cell epithelium surface in urinary disorders and chronic processes cannot be ruled out. Importantly, our data indicate that calprotectin can induce abacterial inflammatory processes in the bladder wall without concomitant leukocyte elevation in urine. Consequently, calprotectin exhibits particularly high diagnostic value as a bladder wall inflammation marker, especially in cases of normal urine test results.Conclusion. The study demonstrates significantly elevated levels of urinary calprotectin, vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6) in female patients diagnosed with chronic recurrent cystitis. Notably, the presence of leukocyturia does not influence urinary calprotectin and VEGF concentrations.Calprotectin emerges as a promising biomarker for detecting inflammation within the bladder wall. Its utility extends to both assessing the inflammatory process activity and evaluating therapeutic efficacy.